BioWorld

Oct. 1, 2009

New Cash in Hand, Threshold Plans Hypoxia Cancer Efforts

Threshold Pharmaceuticals Inc. plans to raise about $35 million through the sale of stock and warrants, money that will help advance its cancer drug pipeline and extend its cash well into 2011. (BioWorld Today) Read More

Dyax Prices 5.5M Shares Ahead of DX-88 Approval, Partnership

Epidemiology Fails to Confirm Link Between Strep, Tics, OCD

Expanded Access Programs Vital, but New Rules Raise Concerns

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for July 14, 2026.

AI-generated illustration of a neuron with tau protein aggregation

AAIC 2026: Age of amyloid is being joined by time of tau

BioWorld

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...

News in brief

BioWorld Asia

BioWorld Asia briefs for July 14, 2026

Combination locked out in ATTR-CM? ‘Dead,’ expert says

BioWorld

The synergy – or lack of it – between knockdown drugs and stabilizers in treating transthyretin (TTR)-mediated amyloid cardiomyopathy (ATTR-CM) became one of the...